| Business Summary | | NexMed,
Inc.
is
a
pharmaceutical
and
medical
technology
company.
The
Company
develops
and
commercializes
therapeutic
products
based
on
proprietary
delivery
systems.
The
Company
is
focusing
its
efforts
on
new
and
patented
pharmaceutical
products
based
on
a
penetration-enhancement,
topical-delivery
technology
known
as
NexACT.
The
Company
is
applying
the
NexACT
technology
to
Alprox-TD,
an
alprostadil
cream
for
the
treatment
of
male
erectile
dysfunction
and
Femprox,
also
an
alprostadil-based
cream,
for
the
treatment
of
female
sexual
arousal
disorder. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NexMed,
Inc.
is
a
medical
and
pharmaceutical
technology
company
focused
on
developing
and
commercializing
topical
alprostadil
treatments
that
incorporate
a
new
penetration
enhancement
technology,
and
the
Viratrol
device.
For
the
six
months
ended
6/30/01,
the
Company
reported
no
revenue.
Net
loss
rose
83%
to
$6.8
million.
Results
reflect
costs
related
to
the
scaling-up
of
U.S.
clinical
trials
and
additional
research
personnel. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Y. Joseph Mo, Ph.D., 53 Chairman,
Pres and CEO | $317K | $1.4M | James Yeager, Ph.D., 54 Director,
VP, R&D and Bus. Devel. | 255K | -- | Vivian Liu, 39 VP-
Corp. Affairs, CFO, Sec. | 191K | 461K | Kenneth Anderson, 54 VP,
Commercial Devel. | 29K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|